TRexBio raises $116.7M in Nasdaq IPO at $14 per share

TRex Bio, Inc. (Nasdaq: TRXB), a clinical-stage biotechnology company based in South San Francisco, California, closed its initial public offering of 8,333,334 shares of common stock at $14.00 per share, according to a press release.

The offering generated approximately $116.7 million in gross proceeds before underwriting discounts, commissions, and other expenses. All shares were sold by TRexBio. The company's stock is listed on the Nasdaq Global Select Market under the ticker symbol "TRXB."

J.P. Morgan, Evercore ISI, Cantor, and Stifel served as lead book-running managers for the offering, with Wedbush PacGrow acting as book-running manager. The registration statement became effective on Oct. 8, 2026, with the SEC under File No. 333-299018.

TRexBio focuses on tissue regulatory T cell biology for the development of immunoregulatory medicines targeting autoimmune and inflammatory diseases.

You May Also Be Interested In

• Harbour Island Acquisition prices $100M IPO on Nasdaq
• Workday to acquire C1.ai, an AI identity governance platform
• Generate Biomedicines and Zealand Pharma strike AI drug deal